Back to Journals » International Journal of Nanomedicine » Nanomedicine for Cancer Immunotherapy

ISSN: 1178-2013


Journal Articles:

Nanomedicine for Cancer Immunotherapy

Cancer Immunotherapy is a therapy used to treat cancer patients that involves or uses components of the immune system, including antibodies (e.g. anti-PD1/PD-L1), vaccines and T cell infusions, which is a revolutionary technology in oncology. Cancer immunotherapy has made great progress in the past decades and it is thought to be an effective strategy for achieving long-term success in cancer treatment. Despite some clinical successes, some issues, including low patient response rates, adverse effects/immune-related toxicities, and acquired immune resistance need to be solved. This Article Collection shows recent progress in cancer immunotherapy by using nanotechnology. We hope this Collection can help researchers to deepen the mechanisms by which tumor cells evade immunity, reveal how nanomedicine can strengthen the anti-tumor immune-response, and discuss how nanomedicine overcomes the challenges and the critical limitations of cancer immunotherapy.

A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation

Carrasco-Díaz LM, Gallardo A, Voltà-Durán E, Virgili AC, Páez D, Villaverde A, Vazquez E, Álamo P, Unzueta U, Casanova I, Mangues R, Alba-Castellon L

International Journal of Nanomedicine 2025, 20:2445-2460

Published Date: 26 February 2025

IL-12-Overexpressed Nanoparticles Suppress the Proliferation of Melanoma Through Inducing ICD and Activating DC, CD8+ T, and CD4+ T Cells

Shen HH, Peng JF, Wang RR, Wang PY, Zhang JX, Sun HF, Liang Y, Li YM, Xue JN, Li YJ, Sun GB, Xie SY

International Journal of Nanomedicine 2024, 19:2755-2772

Published Date: 18 March 2024

Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells

Hu D, Yang R, Wang G, Li H, Fan X, Liang G

International Journal of Nanomedicine 2024, 19:2773-2791

Published Date: 18 March 2024

The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts

Huang Q, Ge Y, He Y, Wu J, Tong Y, Shang H, Liu X, Ba X, Xia D, Peng E, Chen Z, Tang K

International Journal of Nanomedicine 2024, 19:3333-3365

Published Date: 8 April 2024

Selective Glycopolymer Inhibitors of Galectin-3: Supportive Anti-Cancer Agents Protecting Monocytes and Preserving Interferon-Gamma Function

Filipová M, Tavares MR, Hovorková M, Heine V, Nekvasilová P, Křen V, Etrych T, Chytil P, Bojarová P

International Journal of Nanomedicine 2025, 20:6591-6609

Published Date: 24 May 2025

Nanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment

Wang J, Ma J, Tai Z, Li L, Zhang T, Cheng T, Yu J, Zhu Q, Bao L, Chen Z

International Journal of Nanomedicine 2023, 18:7149-7172

Published Date: 1 December 2023

Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth

Shaji SG, Patel P, Mamani UF, Guo Y, Koirala S, Lin CY, Alahmari M, Omoscharka E, Cheng K

International Journal of Nanomedicine 2024, 19:8769-8778

Published Date: 27 August 2024

Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies

Jiang K, Wang Q, Chen XL, Wang X, Gu X, Feng S, Wu J, Shang H, Ba X, Zhang Y, Tang K

International Journal of Nanomedicine 2024, 19:8847-8882

Published Date: 28 August 2024

Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects

Jiang Y, Wang C, Zu C, Rong X, Yu Q, Jiang J

International Journal of Nanomedicine 2024, 19:9459-9486

Published Date: 2 October 2024